Predictive genetic testing for cardiomyopathies

Progress in Pediatric Cardiology

Volumn 23, Issue 1-2, 2007, Pages 33-38

  Chung, Wendy K ^a  

^a Columbia University ^*  (United States)

Author keywords

Genetic testing; Hypertrophic cardiomyopathy; Risk stratification; Sacomere

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ATHLETE; CARDIOMYOPATHY; CLINICAL TRIAL; GENE MUTATION; GENETIC ANALYSIS; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SARCOMERE; SUDDEN DEATH; SYMPTOMATOLOGY;

EID: 34547437301     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.05.002     Document Type: Article

References (21)

1. Zou Y., Song L., Wang Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116 (2004) 14-18
2. Maron B.J. Distinguishing hypertrophic cardiomyopathy from athlete's heart: a clinical problem of increasing magnitude and significance. Heart 91 (2005) 1380-1382
3. Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115 (2007) 773-781
4. Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296 (2006) 1867-1876
5. Lipshultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348 (2003) 1647-1655
6. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 10 (2005) 237-248
7. Ingles J., Doolan A., Chiu C., Seidman J., Seidman C., and Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 42 (2005) e59
8. Van Driest S.L., Vasile V.C., Ommen S.R., et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 44 (2004) 1903-1910
9. Richard P., Charron P., Carrier L., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107 (2003) 2227-2232
10. Watkins H., McKenna W.J., Thierfelder L., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332 (1995) 1058-1064
11. Watkins H., Rosenzweig A., Hwang D.S., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326 (1992) 1108-1114
12. Karibe A., Tobacman L.S., Strand J., et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation 103 (2001) 65-71
13. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 97 (1998) 2230-2236
14. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338 (1998) 1248-1257
15. Maron B.J. Sudden death in young athletes.[see comment]. N Engl J Med 349 (2003) 1064-1075
16. Semsarian C., Ahmad I., Giewat M., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109 (2002) 1013-1020
17. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
18. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001) 789-791
19. Tsybouleva N., Zhang L., Chen S., et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 109 (2004) 1284-1291
20. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 57 (1995) 1233-1241
21. van Langen I.M., Birnie E., Schuurman E., et al. Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: a survey. Clin Genet 68 (2005) 360-368